## Claims

1. A compound of Formula (I)



(I),

and pharmaceutically acceptable salts, solvates, solvates of salts, or prodrugs thereof, wherein:

| | |
|---|---|
| X | is N or C-$R^3$, |
| Y | is NH, O or absent, |
| $R^1$ | is $L^1$–$R^4$–$L^2$–$R^5$ or $L^1$–$R^4$, |
| $R^2$ | is A, Hal, OH, OA, SH, CN, $NH_2$, $NO_2$, NHA, NH–$L^1$–Ar, NHCOA, NHCO–$L^1$–Ar, $NHSO_2A$, $NHSO_2$–$L^1$–Ar, NHCONHA, NHCONH–$L^1$–Ar, $L^1$–Ar, O- $L^1$–Ar, $L^1$–$R^4$, |
| $L^1$ | is a single bond, methylene, or methyl substituted methylene, wherein the methylene, or the methyl group of the methyl substituted methylene may be unsubstituted or mono- or disubstituted with Hal, OH, CN, $NH_2$, NH(LA), N(LA)$_2$, $NO_2$, COOH, $N_3$, ethenyl or ethynyl, and/or monosubstituted with $R^4$, and in which one or two $CH_2$ groups may be replaced by an O or S atom or by an –NH-, -N(LA)-, -CONH-, -N(LA)COO-, -$SO_2$- or -NHCO- group, |
| $R^3$ | is H, A, Hal, OH, COOH, SH, $NH_2$, $NO_2$ or CN, |
| $R^4$, $R^5$ | each, independently of one another, are Ar, or cyclic A which may be mono- or disubstituted by Hal or LA, |
| $L^2$ | is –NHCO–, -NHCOO-, –NHCONH–, –NHCONA–, –NHCOA–, –O–, –S–, –NH–, –$NHSO_2$–, –$SO_2NH$–, –CONH–, –CONHCONH–, –NHCONHCO–, or –A-, |
| Ar | is a mono- or bicyclic aromatic homo- or heterocycle having 0, 1, 2, 3 or 4 N, O and/or S atoms and 5, 6, 7, 8, 9, or 10 skeleton atoms, which may be |

unsubstituted or, independently of one another, mono-, di- or trisubstituted by Hal, A, OH, SH, OA, $NH_2$, NHA, $NA_2$, $NO_2$, CN, OCN, SCN, COOH, COOA, $CONH_2$, CONHA, $CONA_2$, NHCOA, NHCONHA, $NHCONH_2$, $NHSO_2A$, CHO, COA, $SO_2NH_2$, $SO_2A$ and/or $SO_2Hal$,

and in which a ring N-atom may be substituted by an O-atom to form an N-oxide group,

and in which in the case of a bicyclic aromatic cycle on of the two rings may be partly saturated,

A is unbranched or branched linear or cyclic alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 C atoms, in which one or two $CH_2$ groups may be replaced by an O or S atom and/or by an –NH-, -CO-, -NHCOO-, -NHCONH-. -N(LA)-, -CONH-, -NHCO- or –CH=CH– group, and in which 1-3 H atoms may be replaced by Hal, and in which one or two $CH_3$ groups may be replaced by OH, SH, $NH_2$, NH(LA), $N(LA)_2$, NHCOOH, $NHCONH_2$ or CN,

LA is unbranched or branched, linear alkyl having 1, 2, 3 or 4 C atoms, wherein 1, 2 or 3 H atoms may be replaced by Hal,

Hal is F, Cl, Br or I.

2. Compounds according to Claim 1 and pharmaceutically acceptable salts, solvates, solvates of salts, or prodrugs thereof, wherein

X is N,

Y is NH,

$R^1$ is $L^1$– $R^4$,

$R^2$ is LA, Hal, OH, O(LA), SH, CN, $NH_2$, $NO_2$, NH(LA), NHCO(LA), $NHSO_2$(LA), NHCONH(LA),

$L^1$ is methyl substituted methylene, wherein the methyl group of the methyl substituted methylene is monosubstituted with $NH_2$ or NH(LA), $N(LA)_2$, or cyclic A which may be mono- or disubstituted by Hal or LA,

$R^4$ is a monocyclic aromatic homo- or heterocycle having 0, 1 or 2 N, O and/or S atoms and 5 or 6 skeleton atoms, which may be unsubstituted or, independently of one another, mono-, di- or trisubstituted by Hal, A, OH, SH, OA, $NH_2$, NHA, $NA_2$, $NO_2$, CN, OCN, SCN, COOH, COOA, $CONH_2$, CONHA, $CONA_2$, NHCOA, NHCONHA, $NHCONH_2$, $NHSO_2A$, CHO, COA, $SO_2NH_2$, $SO_2A$ and/or $SO_2Hal$,

A is unbranched or branched linear or cyclic alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 C atoms, in which one or two $CH_2$ groups may be replaced by an O or S atom and/or by an –NH-, -CO-, -NHCOO-, -NHCONH-. -N(LA)-, -CONH-, -NHCO- or –CH=CH– group, and in which 1-3 H atoms may be replaced by Hal, and in which one or two $CH_3$ groups may be replaced by OH, SH, $NH_2$, NH(LA), $N(LA)_2$, $NHCOOH$, $NHCONH_2$ or CN,

LA is unbranched or branched, linear alkyl having 1, 2, 3 or 4 C atoms, wherein 1, 2 or 3 H atoms may be replaced by Hal,

Hal is F, Cl, Br or I.

3. The compound according to Claim 2, in which the residues not designated in greater detail have the meaning indicated in Claim 2, but in which

in Subformula 1

$R^2$ is LA,

in Subformula 2

$L^1$ is methyl substituted methylene, wherein the methyl group of the methyl substituted methylene is monosubstituted with methylamino, dimethylamino or azetidine,

in Subformula 3

$R^4$ is phenyl which is unsubstituted or monosubstituted with Hal,

in Subformula 4

$R^2$ is methyl, ethyl, isopropyl or trifluoromethyl,

in Subformula 5

$L^1$ is methyl substituted methylene, wherein the methyl group of the methyl substituted methylene is monosubstituted with methylamino,

in Subformula 6

$L^1$ is methyl substituted methylene, wherein the methyl group of the methyl substituted methylene is monosubstituted with azetidin-1-yl,

in Subformula 7

$R^4$ is phenyl which is unsubstituted,

in Subformula 8

$R^4$ is phenyl which is meta or para substituted with F or Cl,

in Subformula 9

$R^2$ is LA,

$L^1$ is methyl substituted methylene, wherein the methyl group of the methyl substituted methylene is monosubstituted with methylamino or azetidine,

in Subformula 10

$R^2$ is LA,

$R^4$ is phenyl which is unsubstituted or monosubstituted with Hal,

in Subformula 11

$L^1$ is methyl substituted methylene, wherein the methyl group of the methyl substituted methylene is monosubstituted with methylamino or azetidine,

$R^4$ is phenyl which is unsubstituted or monosubstituted with Hal,

in Subformula 12

$R^2$ is LA,

$L^1$ is methyl substituted methylene, wherein the methyl group of the methyl substituted methylene is monosubstituted with methylamino or azetidine,

$R^4$ is phenyl which is unsubstituted or monosubstituted with Hal,

in Subformula 13

$R^2$ is methyl, ethyl, isopropyl or trifluoromethyl,

$L^1$ is methyl substituted methylene, wherein the methyl group of the methyl substituted methylene is monosubstituted with methylamino or azetidine,

$R^4$ is phenyl which is unsubstituted or monosubstituted with Hal,

in Subformula 14

$R^2$ is LA,

$L^1$ is methyl substituted methylene, wherein the methyl group of the methyl substituted methylene is monosubstituted with methylamino or azetidine,

$R^4$ is phenyl which is meta or para substituted with F or Cl,

in Subformula 15

$R^2$ is methyl, ethyl, isopropyl or trifluoromethyl,

$L^1$ is methyl substituted methylene, wherein the methyl group of the methyl substituted methylene is monosubstituted with methylamino or azetidine,

$R^4$ is phenyl which is meta or para substituted with F or Cl,

in Subformula 16

$R^2$ is methyl, ethyl, isopropyl or trifluoromethyl,

$L^1$ is methyl substituted methylene, wherein the methyl group of the methyl substituted methylene is monosubstituted with methylamino,

$R^4$ is phenyl which is meta or para substituted with F or Cl,

in Subformula 17

$R^2$ is methyl, ethyl, isopropyl or trifluoromethyl,

$L^1$ is methyl substituted methylene, wherein the methyl group of the methyl substituted methylene is monosubstituted with azetidin-1-yl,

$R^4$ is phenyl which is meta or para substituted with F or Cl,

in Subformula 18

$R^2$ is methyl, ethyl, isopropyl or trifluoromethyl,

$L^1$ is methyl substituted methylene, wherein the methyl group of the methyl substituted methylene is monosubstituted with methylamino or azetidine,

$R^4$ is phenyl which is meta substituted with F or Cl,

in Subformula 19

$R^2$ is methyl, ethyl, isopropyl or trifluoromethyl,

$L^1$ is methyl substituted methylene, wherein the methyl group of the methyl substituted methylene is monosubstituted with methylamino or azetidin-1-yl,

$R^4$ is phenyl which is meta substituted with F or Cl,

and pharmaceutically acceptable salts, solvates, solvates of salts, or prodrugs thereof.

4. The compound according to Claim 1, wherein the compound is selected from the group consisting of:

4-{[(1S)-1-(4-fluorophenyl)-2-(methylamino)ethyl]amino}-2-methylquinazoline-8-carboxamide,

4-{[(1S)-1-(3-fluorophenyl)-2-(methylamino)ethyl]amino}-2-methylquinazoline-8-carboxamide,

4-{[(1S)-1-(4-chlorophenyl)-2-(methylamino)ethyl]amino}-2-isopropylquinazoline-8-carboxamide,

4-{[(1S)-1-(4-chlorophenyl)-2-(methylamino)ethyl]amino}-2-methylquinazoline-8-carboxamide,

2-Ethyl-4-{[(1S)-1-(3-fluorophenyl)-2-(methylamino)ethyl]amino}quinazoline-8-carboxamide,

4-{[(1S)-1-(3-Chlorophenyl)-2-(methylamino)ethyl]amino}-2-ethylquinazoline-8-carboxamide,

4-{[(1S)-1-(3-Chlorophenyl)-2-(methylamino)ethyl]amino}-2-methylquinazoline-8-carboxamide,

2-Ethyl-4-{[(1S)-2-(methylamino)-1-phenylethyl]amino}quinazoline-8-carboxamide

4-{[(1S)-1-(4-Chlorophenyl)-2-(methylamino)ethyl]amino}-2-ethylquinazoline-8-carboxamide,

2-Ethyl-4-{[(1S)-1-(4-fluorophenyl)-2-(methylamino)ethyl]amino}quinazoline-8-carboxamide,

2-Methyl-4-{[(1S)-2-(methylamino)-1-phenylethyl]amino}quinazoline-8-carboxamide

4-{[(1S)-1-(3-Fluorophenyl)-2-(methylamino)ethyl]amino}-2-(trifluoromethyl)-quinazoline-8-carboxamide,

4-[(S)-3-Azetidin-1-yl-2-(3-fluorophenyl)-propyl]-2-ethyl-quinazoline-8-carboxylic acid amide,

4-[(S)-3-Azetidin-1-yl-2-phenyl-propyl]-2-methyl-quinazoline-8-carboxylic acid amide

4-[(S)-3-Azetidin-1-yl-2-phenyl-propyl]-2-ethyl-quinazoline-8-carboxylic acid amide

4-[(S)-3-Azetidin-1-yl-2-(4-chlorophenyl)-propyl]-2-methyl-quinazoline-8-carboxylic acid amide,

4-[(S)-3-Azetidin-1-yl-2-(4-chlorophenyl)-propyl]-2-ethyl-quinazoline-8-carboxylic acid amide,

4-[(S)-3-Azetidin-1-yl-2-(4-fluorophenyl)-propyl]-2-methyl-quinazoline-8-carboxylic acid amide,
4-[(S)-3-Azetidin-1-yl-2-(3-fluorophenyl)-propyl]-2-methyl-quinazoline-8-carboxylic acid amide,
4-[(S)-3-Azetidin-1-yl-2-(3-chlorophenyl)-propyl]-2-methyl-quinazoline-8-carboxylic acid amide,
4-[(S)-3-Azetidin-1-yl-2-(4-flourophenyl)-propyl]-2-ethyl-quinazoline-8-carboxylic acid amide,
4-[(S)-3-Azetidin-1-yl-2-(3-chlorophenyl)-propyl]-2-ethyl-quinazoline-8-carboxylic acid amide,
and pharmaceutically acceptable salts, solvates, solvates of salts, or prodrugs thereof.

5. A pharmaceutical composition comprising a compound according to any of claims 1 to 4, or a pharmaceutically acceptable salt, solvate, solvate of a salt, or prodrug thereof, as active ingredient, together with a pharmaceutically acceptable carrier.

6. A compound of any of claims 1 to 4, or a pharmaceutically acceptable salt, solvate, solvate of a salt, or prodrug thereof, for use as a medicament.

7. A compound of any of claims 1 to 4, or a pharmaceutically acceptable salt, solvate, solvate, solvate of a salt, or prodrug thereof, for treating hyperproliferative diseases.

8. The compound of claim 7, or a pharmaceutically acceptable salt, solvate, solvate of a salt, or prodrug thereof, wherein the disease is selected from the group consisting of cancer, inflammation, pancreatitis or kidney disease, pain, benign hyperplasia of the skin, restenosis, prostate, diseases related to vasculogenesis or angiogenesis, tumor angiogenesis, skin diseases selected from psoriasis, eczema, and sclerodema, diabetes, diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, hemangioma, glioma, melanoma and Kaposi's sarcoma.

9. Use of a compound of any of claims 1 to 4, or a pharmaceutically acceptable salt, solvate, solvate of a salt, or prodrug thereof, for the preparation of a medicament for the treatment of hyperproliferative diseases.

10. Use according to claim 9 wherein the disease is selected from the group consisting of cancer, inflammation, pancreatitis or kidney disease, pain, benign hyperplasia of the skin, restenosis, prostate, diseases related to vasculogenesis or angiogenesis, tumor angiogenesis, skin diseases selected from psoriasis, eczema, and sclerodema, diabetes, diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, hemangioma, glioma, melanoma and Kaposi's sarcoma.

11. A method for treating hyperproliferative diseases, comprising administering to a subject a compound of any of claims 1 to 4, or a pharmaceutically acceptable salt, solvate, solvate of a salt, or prodrug thereof.

12. The method of claim 11, wherein the disease is selected from the group consisting of cancer, inflammation, pancreatitis or kidney disease, pain, benign hyperplasia of the skin, restenosis, prostate, diseases related to vasculogenesis or angiogenesis, tumor angiogenesis, skin diseases selected from psoriasis, eczema, and sclerodema, diabetes, diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, hemangioma, glioma, melanoma and Kaposi's sarcoma.

13. Set (kit) consisting of separate packs of

a) an effective amount of a compound according to one or more of Claims 1 to 4 or a pharmaceutically acceptable salt, solvate, solvate of a salt, or prodrug thereof, and

b) an effective amount of a further medicament active ingredient.

14. Process for the manufacture of compounds of Formula (I),
wherein X is N and Y is NH, and all other substituents have the meaning as defined for Formula (I) in Claim 1, wherein a carboxylic acid ester of Formula (IV)




(IV),

is reacted with a compound of Formula (III)

H-Y-$R^1$

(III),

to yield a compound of Formula (II)



(II),

which is finally converted into the carboxylic amide of Formula (I)



(I).

**Claims**

1. A compound of Formula (I)



(I),

and pharmaceutically acceptable salts, solvates, or solvates of salts thereof, wherein:

| | |
|---|---|
| X | is N or C-$R^3$, |
| Y | is NH, O or absent, |
| $R^1$ | is $L^1$–$R^4$–$L^2$–$R^5$ or $L^1$–$R^4$, |
| $R^2$ | is A, Hal, OH, OA, SH, CN, $NH_2$, $NO_2$, NHA, NH–$L^1$–Ar, NHCOA, NHCO–$L^1$–Ar, $NHSO_2A$, $NHSO_2$–$L^1$–Ar, NHCONHA, NHCONH–$L^1$–Ar, $L^1$–Ar, O- $L^1$–Ar, $L^1$–$R^4$, |
| $L^1$ | is a single bond, methylene, or methyl substituted methylene, wherein the methylene, or the methyl group of the methyl substituted methylene may be unsubstituted or mono- or disubstituted with Hal, OH, CN, $NH_2$, NH(LA), $N(LA)_2$, $NO_2$, COOH, $N_3$, ethenyl or ethynyl, and/or monosubstituted with $R^4$, and in which one or two $CH_2$ groups may be replaced by an O or S atom or by an –NH-, -N(LA)-, -CONH-, -N(LA)COO-, $-SO_2$- or -NHCO- group, |
| $R^3$ | is H, A, Hal, OH, COOH, SH, $NH_2$, $NO_2$ or CN, |
| $R^4$, $R^5$ | each, independently of one another, are Ar, or cyclic A which may be mono- or disubstituted by Hal or LA, |
| $L^2$ | is –NHCO–, -NHCOO-, –NHCONH–, –NHCONA–, –NHCOA–, –O–, –S–, –NH–, $–NHSO_2–$, $–SO_2NH–$, –CONH–, –CONHCONH–, –NHCONHCO–, or –A-, |
| Ar | is a mono- or bicyclic aromatic homo- or heterocycle having 0, 1, 2, 3 or 4 N, O and/or S atoms and 5, 6, 7, 8, 9, or 10 skeleton atoms, which may be unsubstituted or, independently of one another, mono-, di- or trisubstituted by Hal, A, OH, SH, OA, $NH_2$, NHA, $NA_2$, $NO_2$, CN, OCN, SCN, COOH, |

COOA, $CONH_2$, CONHA, $CONA_2$, NHCOA, NHCONHA, $NHCONH_2$, $NHSO_2A$, CHO, COA, $SO_2NH_2$, $SO_2A$ and/or $SO_2Hal$,
and in which a ring N-atom may be substituted by an O-atom to form an N-oxide group,
and in which in the case of a bicyclic aromatic cycle on of the two rings may be partly saturated,

A is unbranched or branched linear or cyclic alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 C atoms, in which one or two $CH_2$ groups may be replaced by an O or S atom and/or by an –NH-, -CO-, -NHCOO-, -NHCONH-. -N(LA)-, -CONH-, -NHCO- or –CH=CH– group, and in which 1-3 H atoms may be replaced by Hal, and in which one or two $CH_3$ groups may be replaced by OH, SH, $NH_2$, NH(LA), $N(LA)_2$, NHCOOH, $NHCONH_2$ or CN,

LA is unbranched or branched, linear alkyl having 1, 2, 3 or 4 C atoms, wherein 1, 2 or 3 H atoms may be replaced by Hal,

Hal is F, Cl, Br or I.

2. Compounds according to Claim 1 and pharmaceutically acceptable salts, solvates, or solvates of salts thereof, wherein

X is N,

Y is NH,

$R^1$ is $L^1– R^4$,

$R^2$ is LA, Hal, OH, O(LA), SH, CN, $NH_2$, $NO_2$, NH(LA), NHCO(LA), $NHSO_2$(LA), NHCONH(LA),

$L^1$ is methyl substituted methylene, wherein the methyl group of the methyl substituted methylene is monosubstituted with $NH_2$ or NH(LA), $N(LA)_2$, or cyclic A which may be mono- or disubstituted by Hal or LA,

$R^4$ is a monocyclic aromatic homo- or heterocycle having 0, 1 or 2 N, O and/or S atoms and 5 or 6 skeleton atoms, which may be unsubstituted or, independently of one another, mono-, di- or trisubstituted by Hal, A, OH, SH, OA, $NH_2$, NHA, $NA_2$, $NO_2$, CN, OCN, SCN, COOH, COOA, $CONH_2$, CONHA, $CONA_2$, NHCOA, NHCONHA, $NHCONH_2$, $NHSO_2A$, CHO, COA, $SO_2NH_2$, $SO_2A$ and/or $SO_2Hal$,

A is unbranched or branched linear or cyclic alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 C atoms, in which one or two $CH_2$ groups may be replaced by an O or S atom and/or by an –NH-, -CO-, -NHCOO-, -NHCONH-. -N(LA)-, -CONH-,

-NHCO- or –CH=CH– group, and in which 1-3 H atoms may be replaced by Hal, and in which one or two $CH_3$ groups may be replaced by OH, SH, $NH_2$, NH(LA), $N(LA)_2$, NHCOOH, $NHCONH_2$ or CN,

LA is unbranched or branched, linear alkyl having 1, 2, 3 or 4 C atoms, wherein 1, 2 or 3 H atoms may be replaced by Hal,

Hal is F, Cl, Br or I.

3. The compound according to Claim 2, in which the residues not designated in greater detail have the meaning indicated in Claim 2, but in which

in Subformula 1

$R^2$ is LA,

in Subformula 2

$L^1$ is methyl substituted methylene, wherein the methyl group of the methyl substituted methylene is monosubstituted with methylamino, dimethylamino or azetidine,

in Subformula 3

$R^4$ is phenyl which is unsubstituted or monosubstituted with Hal,

in Subformula 4

$R^2$ is methyl, ethyl, isopropyl or trifluoromethyl,

in Subformula 5

$L^1$ is methyl substituted methylene, wherein the methyl group of the methyl substituted methylene is monosubstituted with methylamino,

in Subformula 6

$L^1$ is methyl substituted methylene, wherein the methyl group of the methyl substituted methylene is monosubstituted with azetidin-1-yl,

in Subformula 7

$R^4$ is phenyl which is unsubstituted,

in Subformula 8

$R^4$ is phenyl which is meta or para substituted with F or Cl,

in Subformula 9

$R^2$ is LA,

$L^1$ is methyl substituted methylene, wherein the methyl group of the methyl substituted methylene is monosubstituted with methylamino or azetidine,

in Subformula 10

$R^2$ is LA,

$R^4$ is phenyl which is unsubstituted or monosubstituted with Hal,

in Subformula 11

$L^1$ is methyl substituted methylene, wherein the methyl group of the methyl substituted methylene is monosubstituted with methylamino or azetidine,

$R^4$ is phenyl which is unsubstituted or monosubstituted with Hal,

in Subformula 12

$R^2$ is LA,

$L^1$ is methyl substituted methylene, wherein the methyl group of the methyl substituted methylene is monosubstituted with methylamino or azetidine,

$R^4$ is phenyl which is unsubstituted or monosubstituted with Hal,

in Subformula 13

$R^2$ is methyl, ethyl, isopropyl or trifluoromethyl,

$L^1$ is methyl substituted methylene, wherein the methyl group of the methyl substituted methylene is monosubstituted with methylamino or azetidine,

$R^4$ is phenyl which is unsubstituted or monosubstituted with Hal,

in Subformula 14

$R^2$ is LA,

$L^1$ is methyl substituted methylene, wherein the methyl group of the methyl substituted methylene is monosubstituted with methylamino or azetidine,

$R^4$ is phenyl which is meta or para substituted with F or Cl,

in Subformula 15

$R^2$ is methyl, ethyl, isopropyl or trifluoromethyl,

$L^1$ is methyl substituted methylene, wherein the methyl group of the methyl substituted methylene is monosubstituted with methylamino or azetidine,

$R^4$ is phenyl which is meta or para substituted with F or Cl,

in Subformula 16

$R^2$ is methyl, ethyl, isopropyl or trifluoromethyl,

$L^1$ is methyl substituted methylene, wherein the methyl group of the methyl substituted methylene is monosubstituted with methylamino,

$R^4$ is phenyl which is meta or para substituted with F or Cl,

in Subformula 17

$R^2$ is methyl, ethyl, isopropyl or trifluoromethyl,

$L^1$ is methyl substituted methylene, wherein the methyl group of the methyl substituted methylene is monosubstituted with azetidin-1-yl,

$R^4$ is phenyl which is meta or para substituted with F or Cl,

in Subformula 18

$R^2$ is methyl, ethyl, isopropyl or trifluoromethyl,

$L^1$ is methyl substituted methylene, wherein the methyl group of the methyl substituted methylene is monosubstituted with methylamino or azetidine,

$R^4$ is phenyl which is meta substituted with F or Cl,

in Subformula 19

$R^2$ is methyl, ethyl, isopropyl or trifluoromethyl,

$L^1$ is methyl substituted methylene, wherein the methyl group of the methyl substituted methylene is monosubstituted with methylamino or azetidin-1-yl,

$R^4$ is phenyl which is meta substituted with F or Cl,

and pharmaceutically acceptable salts, solvates, or solvates of salts thereof.

4. The compound according to Claim 1, wherein the compound is selected from the group consisting of:
4-{[(1S)-1-(4-fluorophenyl)-2-(methylamino)ethyl]amino}-2-methylquinazoline-8-carboxamide,

4-{[(1S)-1-(3-fluorophenyl)-2-(methylamino)ethyl]amino}-2-methylquinazoline-8-carboxamide,
4-{[(1S)-1-(4-chlorophenyl)-2-(methylamino)ethyl]amino}-2-isopropylquinazoline-8-carboxamide,
4-{[(1S)-1-(4-chlorophenyl)-2-(methylamino)ethyl]amino}-2-methylquinazoline-8-carboxamide,
2-Ethyl-4-{[(1S)-1-(3-fluorophenyl)-2-(methylamino)ethyl]amino}quinazoline-8-carboxamide,
4-{[(1S)-1-(3-Chlorophenyl)-2-(methylamino)ethyl]amino}-2-ethylquinazoline-8-carboxamide,
4-{[(1S)-1-(3-Chlorophenyl)-2-(methylamino)ethyl]amino}-2-methylquinazoline-8-carboxamide,
2-Ethyl-4-{[(1S)-2-(methylamino)-1-phenylethyl]amino}quinazoline-8-carboxamide
4-{[(1S)-1-(4-Chlorophenyl)-2-(methylamino)ethyl]amino}-2-ethylquinazoline-8-carboxamide,
2-Ethyl-4-{[(1S)-1-(4-fluorophenyl)-2-(methylamino)ethyl]amino}quinazoline-8-carboxamide,
2-Methyl-4-{[(1S)-2-(methylamino)-1-phenylethyl]amino}quinazoline-8-carboxamide
4-{[(1S)-1-(3-Fluorophenyl)-2-(methylamino)ethyl]amino}-2-(trifluoromethyl)-quinazoline-8-carboxamide,
4-[(S)-2-Azetidin-1-yl-1-(3-fluorophenyl)-ethylamino]-2-ethyl-quinazoline-8-carboxylic acid amide,
4-[(S)-2-Azetidin-1-yl-1-phenyl-ethylamino]-2-methyl-quinazoline-8-carboxylic acid amide
4-[(S)-2-Azetidin-1-yl-1-phenyl-ethylamino]-2-ethyl-quinazoline-8-carboxylic acid amide
4-[(S)-2-Azetidin-1-yl-1-(4-chlorophenyl)- ethylamino]-2-methyl-quinazoline-8-carboxylic acid amide,
4-[(S)-2-Azetidin-1-yl-1-(4-chlorophenyl)- ethylamino]-2-ethyl-quinazoline-8-carboxylic acid amide,
4-[(S)-2-Azetidin-1-yl-1-(4-fluorophenyl)- ethylamino]-2-methyl-quinazoline-8-carboxylic acid amide,
4-[(S)-2-Azetidin-1-yl-1-(3-fluorophenyl)- ethylamino]-2-methyl-quinazoline-8-carboxylic acid amide,
4-[(S)-2-Azetidin-1-yl-1-(3-chlorophenyl)- ethylamino]-2-methyl-quinazoline-8-carboxylic acid amide,
4-[(S)-2-Azetidin-1-yl-1-(4-fluorophenyl)- ethylamino]-2-ethyl-quinazoline-8-carboxylic acid amide,

4-[(S)-2-Azetidin-1-yl-1-(3-chlorophenyl)- ethylamino]-2-ethyl-quinazoline-8-carboxylic acid amide,
and pharmaceutically acceptable salts, solvates, or solvates of salts thereof.

5. A pharmaceutical composition comprising a compound according to any of claims 1 to 4, or a pharmaceutically acceptable salt, solvate, or solvate of a salt thereof, as active ingredient, together with a pharmaceutically acceptable carrier.

6. A compound of any of claims 1 to 4, or a pharmaceutically acceptable salt, solvate, or solvate of a salt thereof, for use as a medicament.

7. A compound of any of claims 1 to 4, or a pharmaceutically acceptable salt, solvate, solvate, or solvate of a salt thereof, for use in the treatment of hyperproliferative diseases.

8. The compound for use according to claim 7, or a pharmaceutically acceptable salt, solvate, or solvate of a salt thereof, wherein the disease is selected from the group consisting of cancer, preferably chosen from breast, colorectal, lung, prostate or pancreatic cancer or glioblastoma.

9. Process for the manufacture of compounds of Formula (I),
wherein X is N and Y is NH, and all other substituents have the meaning as defined for Formula (I) in Claim 1, wherein a carboxylic acid ester of Formula (IV)




(IV),

is reacted with a compound of Formula (III)

$H\text{-}Y\text{-}R^1$

(III),

to yield a compound of Formula (II)



(II),

which is finally converted into the carboxylic amide of Formula (I)



(I).